Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is positioned for a positive financial outlook due to its innovative TRACER platform, which is expected to generate revenue through collaborations advancing to clinical trials in the 2030s. The company has demonstrated promising preclinical results, including a substantial reduction in tau messenger RNA and protein levels in non-human primates, indicating potential efficacy and lower exposure levels compared to existing therapies. Additionally, comparisons of its non-viral NeuroShuttle's performance highlight key advantages in durability and safety, suggesting that Voyager’s approach may offer improved treatment outcomes for neurological diseases.

Bears say

Voyager Therapeutics Inc. has faced challenges in advancing its gene therapy pipeline, which includes notable programs such as Anti-tau Antibody (VY-TAU01) and SOD1 Silencing Gene Therapy. Recent financial reports indicate a significant increase in operating losses, raising concerns about the company's ability to sustain its research and development expenses without additional funding. Furthermore, delayed clinical trial progress and regulatory hurdles may impede Voyager's pathway to commercialization, contributing to a diminished outlook on its stock performance.

Voyager Therapeutics (VYGR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 7 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.